# Safinamide for Levodopa-induced Dyskinesia (PD-LID)

> **NCT03987750** · PHASE3 · WITHDRAWN · sponsor: **Zambon SpA**

## Conditions studied

- Dyskinesia, Drug-Induced
- Parkinson Disease

## Interventions

- **DRUG:** Safinamide Methanesulfonate 150mg
- **DRUG:** Safinamide Methanesulfonate 100mg
- **DRUG:** Safinamide Methanesulfonate matching placebo

## Key facts

- **NCT ID:** NCT03987750
- **Lead sponsor:** Zambon SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10
- **Primary completion:** 2021-04
- **Final completion:** 2021-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** drug development plan has been updated
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987750, "Safinamide for Levodopa-induced Dyskinesia (PD-LID)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03987750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*